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ORIGINAL ARTICLE
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Background: Placental trophoblast can be considered to be pseudomalignant tissue and the pathogenesis
of gestational trophoblastic diseases remains to be clarified.
Aims: To examine the role of caspases 8 and 10, identified by differential expression, on trophoblast
tumorigenesis.
Methods: cDNA array hybridisation was used to compare gene expression profiles in choriocarcinoma
cell lines (JAR, JEG, and BeWo) and normal first trimester human placentas, followed by confirmation with
quantitative real time polymerase chain reaction and immunohistochemistry. Caspase 10 and its closely
related family member caspase 8 were analysed.
Results: Downregulation of caspase 10 in choriocarcinoma was detected by both AtlasTM human cDNA
expression array and AtlasTM human 1.2 array. Caspase 10 mRNA expression was significantly lower in
hydatidiform mole (p = 0.035) and chorioarcinoma (p = 0.002) compared with normal placenta. The
caspase 8 and 10 proteins were expressed predominantly in the cytotrophoblast and syncytiotrophoblast,
respectively, with significantly lower expression in choriocarcinomas than other trophoblastic tissues
(p , 0.05). Immunoreactivity for both caspase 8 and 10 correlated with the apoptotic index previously
assessed by terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (p = 0.02 and
p = 0.04, respectively) and M30 (p , 0.001 and p = 0.003, respectively) approaches.
Conclusions: These results suggest that the downregulation of capases 8 and 10 might contribute to the
pathogenesis of choriocarcinoma.
G
estational trophoblastic disease (GTD) encompasses a
heterogeneous set of diseases arising from abnormal
trophoblast tissue, and includes hydatidiform mole
(HM), invasive mole, choriocarcinoma (CCA), placental site
trophoblastic tumour, and epithelioid trophoblastic tumour.
HM mole can be subclassified into complete HM and partial
HM. GTD is a unique disease that arises from allografting of
the conceptus, and has the potential for local invasion and
widespread metastasis, with varying degrees of aggressive-
ness. Although CCAs are highly malignant, most HMs regress
spontaneously after suction evacuation, although about 8–
30% of patients with HM will develop persistent gestational
trophoblastic neoplasia (GTN), as reflected by persistent or
rising human chorionic gonadotrophin (hCG) concentra-
tions, and will require chemotherapy. The pathogenesis of
GTD remains unclear and few parameters have been found to
be useful in predicting the outcome of HM.
‘‘Gestational trophoblastic disease is a unique disease that
arises from allografting of the conceptus, and has the
potential for local invasion and widespread metastasis,
with varying degrees of aggressiveness’’
cDNA array analysis can be used to investigate the
expression profile of genes involved in human carcinogenesis,
cell cycle regulation, apoptosis, transcription regulation, DNA
repair and synthesis, and receptor signalling, in addition to
growth factors and cell adhesion molecules, and perhaps lead
to a better understanding of disease.1
In our previous studies, we demonstrated the differential
expression of individual oncogenes in GTD,2–5 and showed
that telomerase activity and apoptosis are probably related to
the clinical outcome of HM.2 6 7 Recently, we used apoptotic
cDNA arrays, and identified Mcl-1, an apoptosis related gene,
as being related to the clinical progression of HM.8 In our
present study, we compared the gene expression profiles of
normal first trimester placentas and choriocarcinoma cell
lines using more comprehensive cDNA arrays, followed by
confirmatory gene expression studies by quantitative reverse
transcription polymerase chain reaction (RT-PCR) and
immunohistochemistry. The results were correlated with
the clinicopathological and biological parameters in an
attempt to improve our understanding of the pathogenesis
of GTD.
MATERIALS AND METHODS
Tissues and cell l ines
JAR, JEG, and BeWo CCA cell lines available from ATCC
(American Type Culture Collection, Maryland, USA) were
cultured.
HMs were treated by suction evacuation after ultrasound
and clinical diagnosis. First trimester placentas, second
trimester placentas, and term placentas were collected after
induced abortion or term delivery. Some tissues were snap
frozen and stored at 270 C˚ until RNA extraction. Approval
was obtained from the ethics committee of the University of
Hong Kong for the collection of placental tissue and tissue
from gestational trophoblastic disease. Clinical follow up data
were retrieved in patients with a diagnosis of HM. GTN was
diagnosed if there was a plateau in the hCG concentration for
four weeks or if there was a further increase in the hCG
concentration for three consecutive weeks.9
Abbreviations: CCA, choriocarcinoma; GTD, gestational trophoblastic
disease; GTN, gestational trophoblastic neoplasia; hCG, human
chorionic gonadotrophin; HM, hydatidiform mole; PCR, polymerase
chain reaction; RT, reverse transcription; TUNEL, terminal
deoxynucleotidyl transferase mediated dUTP nick end labelling
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Pooled RNA from three first trimester placentas (gesta-
tional age, 8–10 weeks) and three CCA cell lines were used
for the cDNA array experiments. For the real time RT-PCR
experiments, nine first trimester placentas (gestational age,
7–12 weeks), two second trimester placentas (gestational age,
18–20 weeks), and four term placentas (gestational age, 38–
41 weeks), in addition to 13 HMs that regressed (gestational
age, 7–24 weeks) and six HMs that developed GTN
(gestational age, 6–20 weeks) were used. Among the HMs
that developed GTN, two patients developed metastasis to the
lungs and one patient had an additional metastasis to the
liver.
For the immunohistochemical study, formalin fixed,
paraffin wax embedded tissues from 14 partial HMs
(gestational age, 8–17 weeks), 34 complete HMs (gestational
age, 8–28 weeks), and seven CCAs were selected randomly. In
addition, 14 normal first trimester placentas (gestational age,
8–13 weeks), 13 term placentas (gestational age, 38–41
weeks), and 11 spontaneous abortions (gestational age, 5–12
weeks) were also included. Thirty two of the HMs sponta-
neously regressed after suction evacuation, whereas 16
patients developed GTN and required chemotherapy. The
histological features of these cases were reviewed using
haematoxylin and eosin stained sections.10–12 The diagnosis in
most cases was confirmed by fluorescent microsatellite
genotyping after microdissection and with chromosome in
situ hybridisation to analyse ploidy status.13 14
RNA extraction and cDNA array analysis
Total RNA was extracted and the mRNA was then isolated
using the QuickPrep Micro mRNA purification kit
(Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, UK). Frozen sections were histologically
assessed to ensure that over 90% of the tissue was
trophoblast. Equal amounts of pooled mRNA from three
normal first trimester placentas (gestational age, 8–10 weeks)
and three cell lines were used for probe synthesis. The
differential gene expression experiments used the commer-
cially available AtlasTM human cDNA expression array and
the AtlasTM human 1.2 array (Clontech, Palo Alto, California,
USA), which analysed 588 and 1176 cDNA tags, respectively,
related to a wide range of biological pathways. The probes
were labelled with [a-33P]dATP, hybridised on to the
membranes, washed, and exposed to x ray films. The
intensities of the dotted genes were measured with
AtlasImageTM (Clontech).
Real time RT-PCR
Primers and TaqMan probes were designed to span three
exons so that they were specific to the target transcripts and
to eliminate amplification from genomic DNA. Caspase 8:
(exon 6) forward primer, 59-CCG CAA AGG AAG CAA GAA
C-39; (exon 8) reverse primer, 59-AAT TCT GAT CTG CTC ACT
TCT TCT G-39; and TaqMan probe, 59-FAM-TGC CTT GAT
GTT ATT CCA GAG ACT CCA GGA-TAMRA-39 (accession
number NM_001228). Caspase 10: (exon 3) forward primer,
59-CAG AAG GCA TTG ACT CAG AGA ACT-39; (exon 5)
reverse primer, 59-GAT ACG ACT CGG CTT CCT TGT-39; and
TaqMan probe, 59-FAM-CTT CCT TCT GAA AGA CTC GCT
TCC-TAMRA-39 (accession number NM_032974). The
expression of caspases 8 and 10 was normalised against the
expression of the housekeeping gene, TBP (TATA box binding
protein).15 The quantitative real time reaction was carried out
and analysed using the ABI7700 Sequence Detection System
(Applied Biosystems, Foster City, California, USA).
Immunohistochemical staining of caspases 8 and 10
Paraffin wax embedded sections were incubated with
primary goat polyclonal anticaspase 8 (p20; C-20; Santa
Cruz Biotech, Santa Cruz, California, USA) and rabbit
polyclonal anticaspase 10 (Cell Signaling Technology,
Beverly, California, USA). The sections were then developed
with biotinylated secondary antibody (Amersham,
Piscataway, New Jersey, USA), followed by streptavidin–
biotin peroxidase complex (Dako, Glostrup, Denmark).
Freshly prepared 3, 3-diaminobenzidine was used for colour
development and the sections were then counterstained with
Mayer’s haematoxylin.
Figure 1 Immunoreactivity for caspase 8 is found predominantly in the
cytotrophoblast of (A) normal placenta, (B) hydatidiform mole, and (C)
choriocarcinoma.
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Immunostaining for caspases 8 and 10 was scored with
respect to relative intensity on an arbitrary scale: 1, weak; 2,
moderate; and 3, intense. The percentage of positive cells was
also estimated. The values of these two parameters were
multiplied to produce an immunoreactive score, which
ranged from 0 to 300 for each case.
Statistical analysis
Correlations between numerical data were performed using
Pearson’s correlation test. Numerical data that were not
normally distributed were analysed by the Mann-Whitney
test and analysis of variance. A p value less than 0.05 was
taken as significant.
RESULTS
Downregulation of caspase 10 mRNA expression in
CCA cell l ines by cDNA array analysis
Genes with differential expression were defined as upregu-
lated or downregulated if they displayed a twofold difference
in expression. We found a twofold downregulation of caspase
10 using both the Atlas human cDNA expression array and
the Atlas human 1.2 array (data not shown).
Reduced expression of caspases 8 and 10 in HM and
CCA
Quantitative real time RT-PCR confirmed the reduced
expression of caspase 10 in HM (p = 0.035) and CCA
(p = 0.002) when compared with normal placenta (data not
shown).
Immunohistochemical studies show that immunoreactiv-
ity for caspases 8 (fig 1) and 10 (fig 2) was found
predominantly in the cytoplasm of the cytotrophoblast (CT)
and syncytiotrophoblast (ST), respectively, in all the tropho-
blasts studied. No expression of caspase 8 was found in STs,
whereas only weak expression of caspase 10 was found in
CTs. Immunostaining for caspases 8 and 10 was weak in the
intermediate trophoblast infiltrating the decidua.
The amount of caspase 8 and caspase 10 protein was
significantly lower (p , 0.05; tables 1–3) in CCA than in
normal placenta, spontaneous abortion, partial HM, and
complete HM. However, there were no significant difference
among the last four categories except for the marginal
difference in caspase 8 expression between normal placenta
and spontaneous abortion.
The expression of caspases 8 and 10 was not significantly
different between the HMs that subsequently regressed and
those that developed persistent GTN, with or without
metastasis (p = 0.13 and p = 0.5, respectively). Therefore,
there was no correlation between the expression of caspases 8
and 10 and the clinical behaviour of HM.
Correlation with apoptotic markers
The results were also correlated with our previous findings on
apoptotic activity in matched samples.2 7 Caspase 8 and 10
Figure 2 Immunoreactivity for caspase 10 is found predominantly in
the syncytiotrophoblast of (A) normal placenta, (B) hydatidiform mole,
and (C) choriocarcinoma.
Table 1 Caspase 8 index of normal placenta,
spontaneous abortion, hydatidiform mole, and
choriocarcinoma
Range Mean SD
Normal placenta (n = 27) 40–225 139 65.9
Spontaneous abortion (n = 11) 5–180 71 50.5
Partial mole (n = 14) 40–225 115 63.8
Complete mole (n = 34) 20–240 115 55.4
Choriocarcinoma (n = 7) 15–60 30.7 15.4
Table 2 Caspase 10 index of normal placenta,
spontaneous abortion, hydatidiform mole, and
choriocarcinoma
Range Mean SD
Normal placenta (n = 27) 60–150 120 26.2
Spontaneous abortion (n = 11) 40–240 110 53.7
Partial mole (n = 14) 60–255 127 64
Complete mole (n = 34) 60–255 115 60.2
Choriocarcinoma (n = 7) 10–55 34.2 17.4
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immunoreactivity correlated with the apoptotic index, as
assessed by terminal deoxynucleotidyl transferase mediated
dUTP nick end labelling (TUNEL) (p = 0.02 and p = 0.04,
respectively) or M30 (p , 0.001 and p = 0.003, respec-
tively), but not with Bcl-2 expression (p . 0.05).
DISCUSSION
In our two independent cDNA array analyses, caspase 10 was
found to be consistently downregulated in the CCA cell lines,
and was thus selected for further analysis. Human first
trimester placentas were used as controls in an attempt to
reflect the in vivo situation more closely. Decreased expres-
sion of heat shock protein 27 was also seen in CCA cell lines
in our array study, which agrees with previous findings using
a placenta cell line as control.16
Caspase 10, an initiator of death receptor signalling, is
closely related to the sequence of caspase 8.17 The genes for
these two molecules map to the same region of chromosome
2q33–34, so that they might arise from the duplication of one
ancestral gene.18 Shikama detected both caspase 8 and
caspase 10 in the cytoplasm of HeLa cancer cells.19 The
expression of procaspases 8 and 10 in tumour cell lines was
associated with TRAIL (tumour necrosis factor a related
apoptosis inducing ligand) induced apoptosis and was
important in the resistance to chemotherapy.20 21 Moreover,
caspase 10 expression was found to be more abundant in
fetal lung, kidney, and skeletal muscle but not in the
corresponding adult tissues, suggesting that caspase 10
might also play an important role in fetal development.18 22
In our present study, we found significantly lower
expression of caspase 8 and 10 mRNA and/or protein in
CCA and HM compared with non-molar placentas. Our
results support the hypothesis that human cancer cells often
have defects in apoptosis, including deficient expression of
caspases.23 24 For example, downregulation of caspase 1 or 7
appears to be a marker of colonic cancer.25 In contrast,
caspase overexpression may induce apoptosis in a prostate
cancer cell line.26 Thus, the significant downregulation of
caspases 8 and 10 detected in our study may play a role in the
pathogenesis of GTD. However, no significant differences in
the expression of caspases 8 and 10 were seen between
regressive and persistent moles, suggesting that the expres-
sion of these caspases would not be a useful predictor of the
clinical behaviour of HMs.
‘‘Our results support the hypothesis that human cancer
cells often have defects in apoptosis, including deficient
expression of caspases’’
Trophoblasts of the placenta can be considered to be
‘‘pseudomalignant’’ tissue because even normal trophoblasts
display features of malignant cells, such as rapid prolifera-
tion, infiltration of host tissue, and haematogenous dissemi-
nation, and can escape immunological surveillance.
Trophoblasts can be divided into CTs, STs, and intermediate
trophoblasts. CTs consist of proliferating stem cells and
subsequently differentiate and fuse to form STs. It has been
found that different oncogenes are expressed differentially in
CTs and STs.2–5 27–29 Our immunohistochemical staining
analysis showed that caspase 8 expression was limited to
CTs, whereas caspase 10 was expressed predominantly in STs.
With no generative potential, the formation of an ST
depends upon the continuous fusion of the underlying
proliferating CT to replace its aging population.28–31 This
continuous fusion of stem cells also serves to transport fresh
cellular materials such as nucleic acids and enzymes, which
might include caspases, to the ST. In culture conditions, it
was shown that CTs exhibit higher caspase 3, 6, 8, and 9
activity compared with the more differentiated STs,32 and
that caspase 8 expression is a prerequisite for differentiation
and syncytial fusion in CTs.33 Because caspase 10 was only
weakly expressed in CTs but strongly expressed in STs,
caspase 10 activity may start in the CT and accumulate
during syncytial fusion at ST. Caspase 8 expression was
found in CT only; it might become active in the CT but
disappear once syncytial fusion is completed. Our previous
findings from the M30 study also suggested that apoptosis
involving the caspase cascade might be initiated in the CT
and completed in the ST.7 These data appear to support the
view that caspase 8 occupies an upstream position with
respect to caspase 10 in the apoptotic pathway in tropho-
blasts. Alternatively, caspases 8 and 10 may have distinct
roles in death receptor signalling34 35 in apoptosis initiation in
different populations of trophoblasts.
The immunoreactivity of both caspase 8 and caspase 10
correlated with the apoptotic index in GTD assessed by the
M30 and TUNEL approaches in our previous studies.2 7 The
TUNEL technique identifies fragmented DNA formed as a
result of DNA endonuclease activity and helps in assessing
apoptosis at a late stage. The M30 monoclonal antibody
recognises a formalin resistant caspase cleavage site within
cytokeratin 18, after cleavage by caspases 3 and 7. A
significant correlation between caspases 8 and 10 and both
of these apoptotic activity indicators suggested that caspases
8 and 10 are important in the process of apoptosis. In
contrast, neither caspases 8 nor caspase 10 expression
correlated with that of Bcl-2, suggesting that the expression
of Bcl-2 does not influence the expression of caspases 8 and
10 in GTD. Therefore, further studies to elucidate the relation
between Bcl-2 and specific caspases are essential.
Table 3 Comparison of caspase 8 and 10 immunoscore
between normal placenta, spontaneous abortion, partial
mole, complete mole, and choriocarcinoma
Caspase 8 Caspase 10
Normal placenta v spontaneous abortion 0.032* 0.36
Normal placenta v partial mole 0.35 0.93
Normal placenta v complete mole 0.33 0.28
Normal placenta v choriocarcinoma 0.002* 0.002*
Partial mole v spontaneous abortion 0.79 0.60
Partial mole v complete mole 0.77 0.21
Partial mole v choriocarcinoma 0.001 0.001*
Complete mole v spontaneous abortion 0.028* 0.042*
Complete mole v choriocarcinoma ,0.001* ,0.001*
Spontaneous abortion v choriocarcinoma 0.036* 0.002*
Values shown are p values (Mann Whitney test).
*Significant (p,0.05).
Take home messages
N We found significantly lower expression of caspase 8
and 10 mRNA and/or protein in choriocarcinoma and
hydatidiform mole compared with non-molar placentas
N Immunoreactivity for both caspase 8 and caspase 10
correlated with the apoptotic index
N Caspase 10 and its related family member caspase 8
are probably important in the regulation of apoptosis
in trophoblastic tissues and the development of
trophoblastic diseases
N Apoptosis involving the caspase cascade might be
initiated in the cytotrophoblast and completed in the
chorionic villi of the syncytiotrophoblast
182 Fong, Xue, Ngan, et al
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In summary, caspase 10 and its related family member
caspase 8 are probably important in the regulation of
apoptosis in trophoblastic tissues and the development of
GTD. Apoptosis involving the caspase cascade might be
initiated in the CT and completed in the chorionic villi of the
ST stage.
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